ArticleiScience2025
Identification of the client-binding site on the Golgi membrane protein adaptor Vps74/yGOLPH3.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Siamese Twins: The Multimodular Mechanisms of Golgi Maturation and Glycan Synthesis Are Coupled at Their Core.Sub-cellular biochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vps74 and its mammalian counterpart GOLPH3 are COPI associated protein sorting adaptors that function to maintain the cisternal distributions of a diversity of Golgi integral membrane protein clients by binding to their short cytoplasmically exposed N-termini. Here, we identify the client-binding site on yeast GOLPH3 (Vps74) which maps to two evolutionarily conserved loops on the membrane-facing surface, and includes residues mediating binding of GOLPH3s to PI4P, as well as the membrane-binding β hairpin. As an orthogonal approach, we isolated an inhibitory anti-Vps74 nanobody (which also binds to GOLPH3s) with which we corroborate the client-binding site and reveal that Sac1 and Arf1 binding to Vps74 blocks client access. We also identify an additional mode for the recruitment of Vps74 to Golgi membranes whereby the adaptor binds directly to its client N-termini. This study elucidates the molecular mechanism of Vps74 and identifies an inhibitory GOLPH3 nanobody with potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.